Journal of Diabetes Research & Clinical Metabolism

Journal of Diabetes Research & Clinical

ISSN 2050-0866
Original Research

Increased aldosterone in patients with metabolic syndrome; an additional risk factor

Mohamed Abdou1*, Mohamed Sherif AbdElGawad2 and Sahar AlSayed Mohamed3

*Correspondence: Mohamed Abdou

1. Cardiology Department, Zagazig University, Egypt.

Author Affiliations

2. Internal Medicine Department, Mansoura University, Egypt.

3. Clinical Pathology Department, Mansoura University, Egypt.


Background: Patients with metabolic syndrome (MSyn) are prone to increased cardiovascular morbidity and mortality, although the underlying mechanisms including plasma aldosterone (PA) are not yet fully known.

Aim: Evaluate the association of PA with the MSyn and each of its components.

Methods: 46 patients with MSyn and 25 healthy subjects as a control were subjected to measurements of BMI, waist circumference, office BP & HR, 24-hour BP monitoring, fasting blood sugar (FBS), lipid profile, serum sodium & potassium, serum insulin, insulin resistance calculation, plasma renin activity (PRA) and PA concentrations.

Results: PA concentrations, but not PRA,were significantly higher in MSyn patients (P 0.001, P 0.770 respectively).HR was significantly increased in MSyn patients compared to controls (P 0.024) .There were significant positive correlation between PA level and BMI, waist circumference, SBP, DBP, s.triglycerides,FBS and insulin resistance (r 0.947, P < 0.0001,r 0.829, P < 0.0001, r 0.885, P < 0.0001, r 0.831, P < 0.0001, r 0.611, P < 0.0001, r 0.851, P < 0.0001, r 0.712, P < 0.0001 respectively). A significant negative correlation was present between PA level and HDL-C (r - 0.443 ,P < 0.002). BMI & SBP were the only independent factors affecting PA level by regression analysis. In contrast to PRA, PA tended to increase with an increasing number of MSyn risk factors. In conclusion, PA is associated with MSyn and its components suggesting the link between aldosterone and several cardiovascular risk factors and this may address the possible beneficial effects of aldosterone blockade in those patients with MSyn.

Key words: Metabolic syndrome, plasma aldosterone, plasma renin activitys

ISSN 2050-0866
Volume 2
Abstract Download